Further improving the cognitive effect profile of electroconvulsive therapy (ECT): The case for studying carbamylated erythropoietin☆

Add time:09/01/2019    Source:sciencedirect.com

Electroconvulsive therapy (ECT) remains the most effective acute treatment for severe depression and several other psychiatric illnesses. However, its use has been limited by concerns about cognitive adverse effects. ECT may cause temporary cognitive impairment in some patients, typically anterograde amnesia for 1–2 weeks after a course of treatment, and circumscribed retrograde amnesia. These cognitive effects largely disappear within days to weeks after treatment. Efforts to find a pharmacological agent to reduce the cognitive effects of ECT have largely been unsuccessful, with the possible exception of thyroid hormone. We review the literature on pharmacological attempts to attenuate ECT’s cognitive effects, and propose a novel neuroprotective and neurotrophic agent, carbamylated erythropoietin (CEPO), for this indication.

We also recommend Trading Suppliers and Manufacturers of ect protein (cas 136111-12-1). Pls Click Website Link as below: cas 136111-12-1 suppliers

Prev:Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only
Next:Psychiatrie biologiqueECT : de la neuroplasticité aux mécanismes d’actionECT : from neuronal plasticity to mechanisms underlying antidepressant medication effect)